These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 34382671

  • 1. SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.
    Sergieva S, Mangaldgiev R, Dimcheva M, Nedev K, Zahariev Z, Robev B.
    Nucl Med Rev Cent East Eur; 2021; 24(2):70-81. PubMed ID: 34382671
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Duncan I, Ingold N, Martinez-Marroquin E, Paterson C.
    Prostate; 2023 Jul; 83(10):970-979. PubMed ID: 37051636
    [Abstract] [Full Text] [Related]

  • 4. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 5. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer.
    Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, Song S.
    Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
    Su HC, Zhu Y, Ling GW, Hu SL, Xu XP, Dai B, Ye DW.
    Asian J Androl; 2017 Jan; 19(3):267-271. PubMed ID: 27976632
    [Abstract] [Full Text] [Related]

  • 7. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

  • 8. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 9. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 10. Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
    Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.
    Li B, Duan L, Shi J, Han Y, Wei W, Cheng X, Cao Y, Kader A, Ding D, Wu X, Gao Y.
    Front Oncol; 2022 Apr; 12():1072437. PubMed ID: 36568205
    [Abstract] [Full Text] [Related]

  • 12. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
    Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
    Ghodsirad MA, Pirayesh E, Akbarian R, Javanmard B, Kaghazchi F, Tavakoli M, Fattahi K.
    Urol J; 2020 Jun 23; 17(4):374-378. PubMed ID: 32281092
    [Abstract] [Full Text] [Related]

  • 14. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 15. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb 26; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 16. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 May 26; 44(5):765-775. PubMed ID: 27900519
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Initial experiences with 99mTc-PSMA-SPECT/CT in patients with prostate cancer].
    Farkas I, Besenyi Z, Maráz A, Bajory Z, Palkó A, Sipka G, Pávics L.
    Orv Hetil; 2018 Sep 26; 159(35):1433-1440. PubMed ID: 30146905
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb 26; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.